Up to half of all people living with Alzheimer's Disease in Ireland remain undiagnosed. Now, a new blood test may have the ...

Brain inflammation, while a crucial part of the body's immune response, takes on a detrimental role in Alzheimer's disease.

A complementary drug to combat Alzheimer's disease could target a specific part of the nerve cell protein tau. This is the finding of new research which also offers a better way to measure the effect ...

That's heartening because Alzheimer's disease not only has devastating impact on patients' lives long term, but is also currently incurable. It begins to show up as forgetfulness, and progresses ...

A study reveals that traumatic brain injury alters the small vessels in the brain, resulting in an accumulation of amyloid beta -- a hallmark of Alzheimer's disease. The findings suggest that vascular ...

The exact cause of Alzheimer’s disease has long evaded scientists, but experts typically suggest there are likely several factors (like genetics, environment, and lifestyle) that contribute to ...

The presence of neurofibrillary tangles in the brain is one of the key hallmarks of Alzheimer’s disease. These irregular clumps of protein are closely associated with disease progression.

The exact cause of Alzheimer’s disease has long evaded scientists, but experts typically suggest there are likely several factors (like genetics, environment, and lifestyle) that contribute to its ...

Scientists know that a build-up of specific proteins in the brain is associated with Alzheimer’s disease. However, by the time these proteins have become visible in brain scans, disease ...

Imagine you have just been diagnosed with mild cognitive decline due to Alzheimer’s disease. Your doctor might suggest taking one of the newer medications such as lecanemab or donanemab ...

Brain inflammation, while a crucial part of the body's immune response, takes on a detrimental role in Alzheimer's disease. Unlike the acute, short-lived inflammation that combats infection ...

It often decreases naturally with age. A 2019 study suggests that people with Alzheimer’s disease, even in the early stages of the disease, may have low levels of melatonin secretion in the evening.